UNSPSC 51182601: Diethylstilbestrol/methyltestosterone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51182601 Diethylstilbestrol/methyltestosterone is a Commodity code representing pharmaceutical active ingredients and hormone products purchased by state and local health systems and correctional facilities. The code captures individual pharmaceutical compounds rather than finished dosage forms, though the recent activity shows significant state and local procurement focused on generic multi-source pharmaceuticals distributed through cooperative purchasing frameworks that bundle this and related commodity codes together. State and local buyers under this code include departments of health, departments of corrections, and Medicaid agencies that source through cooperative purchasing alliances, with health systems and clinics supplied through centralized contract vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body, using cooperative purchasing to pool demand across multiple participating states and local facilities for cost leverage.

The Minnesota MMCAP generic multi-source pharmaceuticals RFP (Solicitation Number S1070000015802, due March 26, 2026) exemplifies the current market activity under this code. MMCAP solicits manufacturers to supply comprehensive pharmaceutical product lines including the hormone compounds captured under 51182601, requiring vendors to provide detailed NDC codes, strength, dosage form, and packaging information with cGMP and DSCSA compliance. Products must be available by May 15, 2026, with contracts effective July 1, 2026, and the two-year term optionally extending through June 30, 2028 for incumbent responders. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), demonstrate EDI capability, and accept pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus models. Evaluation weights price competitiveness at 75 percent, with fixed pricing, administrative fee format compliance, EDI capability, and agreement to a 3 percent administrative fee each weighted at 5–10 percent. No specific award value is disclosed; vendors should anticipate the 3 percent administrative fee on all purchases and performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.